Michael V. Knopp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael V. Knopp has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Marco Essig
Department of Radiology, University of Manitoba, Winnipeg, Canada
11 shared publications G Brix
5 shared publications- Hendrik von Tengg-Kobligk
Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
4 shared publications G Van Kaick
3 shared publicationsH Hawighorst
Department of Radiological Diagnostics, German Cancer Research Center, Heidelberg
3 shared publicationsI Zuna
3 shared publications
Latest Publications
- 1 January 2004
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 230 (1) , 55-64
Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine
PURPOSE: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis. MATERIALS AND METHODS: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine. MR imaging was performed before injection (T1-weighted spin-echo [SE] and T2-weighted fast SE acquisitions) and at 1, 3, 5, 7, 9, and 16 minutes after injection (T1-weighted SE acquisitions). Qualitative assessment was performed by blinded off-site readers (for 22 patients) and on-site investigators (for 24 patients) in terms of global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference. Additional quantitative assessment with region-of-interest analysis was performed by off-site readers alone. Statistical analysis of qualitative data was performed with the Wilcoxon signed rank test, whereas a nonparametric approach was adopted for analysis of quantitative data. RESULTS: Significant (P < .05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the global assessment of contrast enhancement. For off-site readers 1 and 2 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patients; and equality was found in five, one, and four patients). Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site investigators for lesion-to-brain contrast and all other qualitative parameters. Off-site quantitative evaluation revealed significantly (P < .05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after injection. CONCLUSION: Significantly superior contrast enhancement of intraaxial enhancing brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine. © RSNA, 2004
- 1 January 2004
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 230 (1) , 55-64
Primary and Secondary Brain Tumors at MR Imaging: Bicentric Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine
PURPOSE: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis. MATERIALS AND METHODS: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine. MR imaging was performed before injection (T1-weighted spin-echo [SE] and T2-weighted fast SE acquisitions) and at 1, 3, 5, 7, 9, and 16 minutes after injection (T1-weighted SE acquisitions). Qualitative assessment was performed by blinded off-site readers (for 22 patients) and on-site investigators (for 24 patients) in terms of global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference. Additional quantitative assessment with region-of-interest analysis was performed by off-site readers alone. Statistical analysis of qualitative data was performed with the Wilcoxon signed rank test, whereas a nonparametric approach was adopted for analysis of quantitative data. RESULTS: Significant (P < .05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the global assessment of contrast enhancement. For off-site readers 1 and 2 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patients; and equality was found in five, one, and four patients). Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site investigators for lesion-to-brain contrast and all other qualitative parameters. Off-site quantitative evaluation revealed significantly (P < .05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after injection. CONCLUSION: Significantly superior contrast enhancement of intraaxial enhancing brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine. © RSNA, 2004
- 19 May 2003
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 17 (6) , 694-702
Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine
To compare intraindividually gadobenate dimeglumine (Gd‐BOPTA) with gadopentetate dimeglumine (Gd‐DTPA) for multi‐station MR Angiography of the run‐off vessels. Twenty‐one randomized healthy volunteers received either Gd‐BOPTA or Gd‐DTPA as a first injection and then the other agent as a second injection after a minimum interval of 6 days. Each agent was administered at a dose of 0.1 mmol/kg bodyweight followed by a 25‐mL saline flush at a single constant flow rate of 0.8 mL/second. Images were acquired sequentially at the level of the pelvis, thigh, and calf using a fast three‐dimensional (3D) gradient echo sequence. Source, subtracted source, maximum intensity projection (MIP), and subtracted MIP image sets from each examination were evaluated quantitatively and qualitatively on a segmental basis involving nine vascular segments. Significantly (P < 0.05) higher signal‐to‐noise and contrast‐to‐noise ratios were noted for Gd‐BOPTA compared to Gd‐DTPA, with the more pronounced differences evident in the more distal vessels. Qualitative assessmentrevealed no differences in the abdominal vasculature, a preference for Gd‐BOPTA in the pelvic vasculature, and markedly better performance for Gd‐BOPTA in the femoral and tibial vasculature. Summation of individual diagnostic quality scores for each segment revealed a significantly (P = 0.0001) better performance for Gd‐BOPTA compared to Gd‐DTPA. Greater vascular enhancement of the run‐off vasculature is obtained after Gd‐BOPTA, particularly in the smaller more distal vessels. Enhancement differences are not merely dose dependent, but may be due to different vascular enhancement characteristics of the agents. J. Magn. Reson. Imaging 2003;17:694–702.
- 19 May 2003
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 17 (6) , 694-702
Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine
To compare intraindividually gadobenate dimeglumine (Gd‐BOPTA) with gadopentetate dimeglumine (Gd‐DTPA) for multi‐station MR Angiography of the run‐off vessels. Twenty‐one randomized healthy volunteers received either Gd‐BOPTA or Gd‐DTPA as a first injection and then the other agent as a second injection after a minimum interval of 6 days. Each agent was administered at a dose of 0.1 mmol/kg bodyweight followed by a 25‐mL saline flush at a single constant flow rate of 0.8 mL/second. Images were acquired sequentially at the level of the pelvis, thigh, and calf using a fast three‐dimensional (3D) gradient echo sequence. Source, subtracted source, maximum intensity projection (MIP), and subtracted MIP image sets from each examination were evaluated quantitatively and qualitatively on a segmental basis involving nine vascular segments. Significantly (P < 0.05) higher signal‐to‐noise and contrast‐to‐noise ratios were noted for Gd‐BOPTA compared to Gd‐DTPA, with the more pronounced differences evident in the more distal vessels. Qualitative assessmentrevealed no differences in the abdominal vasculature, a preference for Gd‐BOPTA in the pelvic vasculature, and markedly better performance for Gd‐BOPTA in the femoral and tibial vasculature. Summation of individual diagnostic quality scores for each segment revealed a significantly (P = 0.0001) better performance for Gd‐BOPTA compared to Gd‐DTPA. Greater vascular enhancement of the run‐off vasculature is obtained after Gd‐BOPTA, particularly in the smaller more distal vessels. Enhancement differences are not merely dose dependent, but may be due to different vascular enhancement characteristics of the agents. J. Magn. Reson. Imaging 2003;17:694–702.
- 1 April 2003
- Vol. 2 (4) , 419-26
Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring.
Functional magnetic resonance imaging is rapidly evolving as a capable noninvasive assessment tool for oncology to improve diagnosis and to monitor therapy. Current clinical techniques are based on microcirculation imaging using extracellular low molecular weight contrast agents such as gadopentetate dimeglumine and analogues. The temporal evolution of the enhancement visualizes the angiogenic properties of lesions with regard to vascular density and permeability, heterogeneity, and changes during therapy.
- 1 April 2003
- Vol. 2 (4) , 419-26
Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring.
Functional magnetic resonance imaging is rapidly evolving as a capable noninvasive assessment tool for oncology to improve diagnosis and to monitor therapy. Current clinical techniques are based on microcirculation imaging using extracellular low molecular weight contrast agents such as gadopentetate dimeglumine and analogues. The temporal evolution of the enhancement visualizes the angiogenic properties of lesions with regard to vascular density and permeability, heterogeneity, and changes during therapy.
- 1 February 2003
- Published by Springer Nature in Der Radiologe
- Vol. 43 (2) , 171-178
Intraindividueller Vergleich dreier Kontrastmittel (Gd-DTPA, Gd-BOPTA und Gd-BT-DO3A) mit der multiphasischen MR-Angiographie
- 1 February 2003
- Published by Springer Nature in Der Radiologe
- Vol. 43 (2) , 171-178
Intraindividueller Vergleich dreier Kontrastmittel (Gd-DTPA, Gd-BOPTA und Gd-BT-DO3A) mit der multiphasischen MR-Angiographie
- 1 December 2002
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 37 (12) , 706-715
Assessment of Gadobenate Dimeglumine for Magnetic Resonance Angiography
To assess the vascular contrasting properties of a new MR contrast agent (gadobenate dimeglumine [Gd-BOPTA]), which presents higher relaxivity because of reversible, weak protein interaction, and, to compare these properties with a standard gadolinium agent. Two phase I trials compared intraindividually: (A) the vascular contrasting properties of Gd-BOPTA at three doses (0.0125, 0.05, and 0.2 mmol/kg body weight) and two flow rates (0.5 and 2.0 mL/s) in 10 volunteers; and (B) 0.1 mmol/kg body weight doses of Gd-BOPTA and Gd-DTPA at 2.0 mL/s using a modified magnetic resonance angiography (MRA) sequence with a temporal resolution of 1 s/f. Quantitative (ROI analysis) and fully blinded qualitative (reader review) assessment of images was performed. A dose of 0.2 mmol/kg resulted in higher maximum intensities, longer median peak widths, and larger areas under the curve than did the lower doses (0.0125 mmol/kg and 0.05 mmol/kg). In the intraindividual comparison, Gd-BOPTA demonstrated significantly better vascular enhancement characteristics in terms of signal peak duration (p < 0.05), maximum signal intensity (p < 0.05), and area under the enhancement curve (p < 0.01). The multireader assessment for overall vascular contrast preferred Gd-BOPTA at p < 0.03. Gd-BOPTA was shown to exhibit preferential and different vascular enhancement properties as compared with Gd-DTPA for MRA.
- 1 December 2002
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 37 (12) , 706-715
Assessment of Gadobenate Dimeglumine for Magnetic Resonance Angiography
To assess the vascular contrasting properties of a new MR contrast agent (gadobenate dimeglumine [Gd-BOPTA]), which presents higher relaxivity because of reversible, weak protein interaction, and, to compare these properties with a standard gadolinium agent. Two phase I trials compared intraindividually: (A) the vascular contrasting properties of Gd-BOPTA at three doses (0.0125, 0.05, and 0.2 mmol/kg body weight) and two flow rates (0.5 and 2.0 mL/s) in 10 volunteers; and (B) 0.1 mmol/kg body weight doses of Gd-BOPTA and Gd-DTPA at 2.0 mL/s using a modified magnetic resonance angiography (MRA) sequence with a temporal resolution of 1 s/f. Quantitative (ROI analysis) and fully blinded qualitative (reader review) assessment of images was performed. A dose of 0.2 mmol/kg resulted in higher maximum intensities, longer median peak widths, and larger areas under the curve than did the lower doses (0.0125 mmol/kg and 0.05 mmol/kg). In the intraindividual comparison, Gd-BOPTA demonstrated significantly better vascular enhancement characteristics in terms of signal peak duration (p < 0.05), maximum signal intensity (p < 0.05), and area under the enhancement curve (p < 0.01). The multireader assessment for overall vascular contrast preferred Gd-BOPTA at p < 0.03. Gd-BOPTA was shown to exhibit preferential and different vascular enhancement properties as compared with Gd-DTPA for MRA.
- 1 October 2000
- Vol. 21 (9) , 1603-1610
Effects of Three Different Doses of a Bolus Injection of Gadodiamide: Assessment of Regional Cerebral Blood Volume Maps in a Blinded Reader Study
BACKGROUND AND PURPOSE: Reconstruction of first-pass bolus information to derive regional cerebral blood volume (rCBV) maps is commonly performed in many centers; however, various protocols with different doses of paramagnetic contrast injections have been reported. We evaluated the dose dependency of rCBV maps in a brain tumor population by using three different doses of gadodiamide injection to evaluate their diagnostic accuracy in blinded reader sessions.
- 1 October 2000
- Vol. 21 (9) , 1603-1610
Effects of Three Different Doses of a Bolus Injection of Gadodiamide: Assessment of Regional Cerebral Blood Volume Maps in a Blinded Reader Study
BACKGROUND AND PURPOSE: Reconstruction of first-pass bolus information to derive regional cerebral blood volume (rCBV) maps is commonly performed in many centers; however, various protocols with different doses of paramagnetic contrast injections have been reported. We evaluated the dose dependency of rCBV maps in a brain tumor population by using three different doses of gadodiamide injection to evaluate their diagnostic accuracy in blinded reader sessions.
- 1 January 2000
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 10 (1) , 5-14
Sicherheitsaspekte bei der Anwendung magnetischer Resonanzverfahren in der medizinischen Diagnostik
- 1 January 2000
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 10 (1) , 5-14
Sicherheitsaspekte bei der Anwendung magnetischer Resonanzverfahren in der medizinischen Diagnostik
- 1 July 1999
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 171 (Bd.2/1) , 38-43
Simultane Bestimmung der Arteriellen Inputfunktion für die Dynamische Suszeptibilitätsgewichtete Magnetresonanztomographie aus der A. carotis interna und der A. cerebri media*
Ziel: Die Bestimmung der arteriellen Inputfunktion (AIF) ist notwendig für die absolute Quantifizierung hämodynamischer Parameter mit der dynamischen suszeptibilitätsgewichteten Magnetresonanztomographie (DSC-MRT). Es wurde untersucht, ob sich die Arteria cerebri media (ACM) ebenso zur Bestimmung der AIF eignet wie die dem Standardverfahren zugrundeliegende Arteria carotis interna (ACI). Methoden: Es wurden ein Standard-1,5 T-MR-Tomograph und eine simultaneous dual FLASH Sequenz (TR/TE1/TE2/α = 32 ms/15 ms/25 ms/10°) verwendet, welche die simultane Akquisition von zwei Schichten ermöglicht. Die Positionierung der zwei Bildgebungsschichten wurde so gewählt, daß die ACI senkrecht geschnitten wurde und Teile der ACM in der zweiten Schicht enthalten waren. Insgesamt wurden 17 DSC-MRT Untersuchungen an 10 Personen vorgenommen. Ergebnisse: Sowohl die Anzahl der AIF-relevanten Pixel wie auch das Integral unter der AIF und die ermittelte Maximalkonzentration der AIF aus der ACM waren kleiner im Vergleich zu den Werten der ACI. Die mittlere Transitzeit sowie die Zeit zum Konzentrationsmaximum waren in der ACM größer, was die computergestützte Identifikation der für die AIF relevanten Pixel kompliziert. Die Analyse von 5 Datensätzen einer einzelnen Person zeigte das gleiche Ergebnis und ergab darüber hinaus deutlich kleinere Schwankungen im Vergleich zu den interpersonellen Schwankungen. Schlußfolgerung: Die Bestimmung der AIF aus der ACI ist verglichen mit der prinzipiell möglichen Bestimmung der AIF aus der ACM vorteilhafter. Die Bestimmung der AIF aus der ACM benötigt noch zusätzliche Korrekturen. Purpose: The determination of the arterial input function (AIF) is necessary for absolute quantification of the regional cerebral blood volume and blood flow using dynamic susceptibility contrast MRI. The suitability of different vessels (ICA - internal carotid artery, MCA - middle cerebral artery) for AIF determination was compared in this study. Methods: A standard 1.5 T MR system and a simultaneous dual FLASH sequence (TR/TE1/TE2/α = 32/15/25/10°) were used to follow a bolus of contrast agent. Slice I was chosen to cut the ICA perpendicularly. Slice II included the MCA. Seventeen data sets from ten subjects were evaluated. Results: The number of AIF-relevant pixels, the area under the AIF and the maximum concentration were all lower when the AIF was determined from the MCA compared to the ICA. Additionally, the mean transit time (MTT) and the time to maximum concentration (TTM) were longer in the MCA, complicating the computerized identification of AIF-relevant pixels. Data from one subject, who was examined five times, demonstrated that the intraindividual variance of the measured parameters was markedly lower than the interpersonal variance. Conclusions: It appears to be advantageous to measure the AIF in the ICA rather than the MCA. 1 Diese Arbeit wurde unterstützt von der Forschungskommission der Medizinischen Fakultät Heidelberg 138/94 und vom BMVg (InSan I, 0595-V-3898).
- 1 July 1999
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 171 (Bd.2/1) , 38-43
Simultane Bestimmung der Arteriellen Inputfunktion für die Dynamische Suszeptibilitätsgewichtete Magnetresonanztomographie aus der A. carotis interna und der A. cerebri media*
Ziel: Die Bestimmung der arteriellen Inputfunktion (AIF) ist notwendig für die absolute Quantifizierung hämodynamischer Parameter mit der dynamischen suszeptibilitätsgewichteten Magnetresonanztomographie (DSC-MRT). Es wurde untersucht, ob sich die Arteria cerebri media (ACM) ebenso zur Bestimmung der AIF eignet wie die dem Standardverfahren zugrundeliegende Arteria carotis interna (ACI). Methoden: Es wurden ein Standard-1,5 T-MR-Tomograph und eine simultaneous dual FLASH Sequenz (TR/TE1/TE2/α = 32 ms/15 ms/25 ms/10°) verwendet, welche die simultane Akquisition von zwei Schichten ermöglicht. Die Positionierung der zwei Bildgebungsschichten wurde so gewählt, daß die ACI senkrecht geschnitten wurde und Teile der ACM in der zweiten Schicht enthalten waren. Insgesamt wurden 17 DSC-MRT Untersuchungen an 10 Personen vorgenommen. Ergebnisse: Sowohl die Anzahl der AIF-relevanten Pixel wie auch das Integral unter der AIF und die ermittelte Maximalkonzentration der AIF aus der ACM waren kleiner im Vergleich zu den Werten der ACI. Die mittlere Transitzeit sowie die Zeit zum Konzentrationsmaximum waren in der ACM größer, was die computergestützte Identifikation der für die AIF relevanten Pixel kompliziert. Die Analyse von 5 Datensätzen einer einzelnen Person zeigte das gleiche Ergebnis und ergab darüber hinaus deutlich kleinere Schwankungen im Vergleich zu den interpersonellen Schwankungen. Schlußfolgerung: Die Bestimmung der AIF aus der ACI ist verglichen mit der prinzipiell möglichen Bestimmung der AIF aus der ACM vorteilhafter. Die Bestimmung der AIF aus der ACM benötigt noch zusätzliche Korrekturen. Purpose: The determination of the arterial input function (AIF) is necessary for absolute quantification of the regional cerebral blood volume and blood flow using dynamic susceptibility contrast MRI. The suitability of different vessels (ICA - internal carotid artery, MCA - middle cerebral artery) for AIF determination was compared in this study. Methods: A standard 1.5 T MR system and a simultaneous dual FLASH sequence (TR/TE1/TE2/α = 32/15/25/10°) were used to follow a bolus of contrast agent. Slice I was chosen to cut the ICA perpendicularly. Slice II included the MCA. Seventeen data sets from ten subjects were evaluated. Results: The number of AIF-relevant pixels, the area under the AIF and the maximum concentration were all lower when the AIF was determined from the MCA compared to the ICA. Additionally, the mean transit time (MTT) and the time to maximum concentration (TTM) were longer in the MCA, complicating the computerized identification of AIF-relevant pixels. Data from one subject, who was examined five times, demonstrated that the intraindividual variance of the measured parameters was markedly lower than the interpersonal variance. Conclusions: It appears to be advantageous to measure the AIF in the ICA rather than the MCA. 1 Diese Arbeit wurde unterstützt von der Forschungskommission der Medizinischen Fakultät Heidelberg 138/94 und vom BMVg (InSan I, 0595-V-3898).
- 1 November 1998
- Vol. 69 (11)
[Volumetric brain findings in late depression. A study with quantified magnetic resonance tomography].
- 1 November 1998
- Vol. 69 (11)
[Volumetric brain findings in late depression. A study with quantified magnetic resonance tomography].
- 15 August 1998
- Vol. 58 (16) , 3598-602
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
Dynamic studies of Gd-based contrast agents in magnetic resonance imaging (MRI) are increasingly being used for tumor characterization as well as for therapy response monitoring. Because detailed knowledge regarding the pathophysiological properties, which in turn are responsible for differences in contrast enhancement, remains fairly undetermined, it was the aim of this study to: (a) examine the association of standard and pharmacokinetic analysis of time-intensity curves in dynamic MRI with histomorphological markers of tumor angiogenesis [microvessel density (MVD) and vascular endothelial growth factor (VEGF)]; and (b) determine the ultimate value of a histomorphological and a dynamic MRI approach by the correlation of those data with disease outcome in patients with primary cancer of the uterine cervix. Pharmacokinetic parameters (amplitude, A; exchange rate constant, k21) and standard parameters [the maximum signal intensity increase over baseline (SI-I) and the steepest signal intensity-upslope per second (SI-U/s)] were calculated from a contrast-enhanced dynamic MRI series in 37 patients with biopsy-proven primary cervical cancer. On the surgical whole mount specimens, histomorphological markers of tumor angiogenesis (MVD and VEGF) were compared to MRI-derived parameters. For MRI and histomorphological data, Kaplan-Meier survival curves were calculated and compared using log-rank statistics. A significant association was found between MVD and A (P < 0.01) and SI-I (P < 0.05). No significant relationships were observed between VEGF expression and all dynamic MRI parameters. Kaplan-Meier curves based on k21 and SI-U/s showed that tumors with high k21 and SI-U/s values had a significantly (P < 0.05 and 0.001, respectively) worse disease outcome than did tumors with low k21 and SI-U/s values. None of the histomorphological gold standard markers for assessing tumor angiogenesis (MVD and VEGF) had any significant power to predict patient survival. It is concluded that in patients with uterine cervical cancer: (a) the pathophysiological basis for differences in dynamic MRI is MVD but not VEGF expression; (b) a functional, dynamic MRI approach (both standard and pharmacokinetic analysis) may be better suited to assess angiogenic activity in terms of patient survival than are the current histomorphological-based markers of tumor angiogenesis; and (c) compared with standard analysis, a simple pharmacokinetic analysis of time-intensity curves is not superior to assess MVD or patient survival.
- 15 August 1998
- Vol. 58 (16) , 3598-602
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
Dynamic studies of Gd-based contrast agents in magnetic resonance imaging (MRI) are increasingly being used for tumor characterization as well as for therapy response monitoring. Because detailed knowledge regarding the pathophysiological properties, which in turn are responsible for differences in contrast enhancement, remains fairly undetermined, it was the aim of this study to: (a) examine the association of standard and pharmacokinetic analysis of time-intensity curves in dynamic MRI with histomorphological markers of tumor angiogenesis [microvessel density (MVD) and vascular endothelial growth factor (VEGF)]; and (b) determine the ultimate value of a histomorphological and a dynamic MRI approach by the correlation of those data with disease outcome in patients with primary cancer of the uterine cervix. Pharmacokinetic parameters (amplitude, A; exchange rate constant, k21) and standard parameters [the maximum signal intensity increase over baseline (SI-I) and the steepest signal intensity-upslope per second (SI-U/s)] were calculated from a contrast-enhanced dynamic MRI series in 37 patients with biopsy-proven primary cervical cancer. On the surgical whole mount specimens, histomorphological markers of tumor angiogenesis (MVD and VEGF) were compared to MRI-derived parameters. For MRI and histomorphological data, Kaplan-Meier survival curves were calculated and compared using log-rank statistics. A significant association was found between MVD and A (P < 0.01) and SI-I (P < 0.05). No significant relationships were observed between VEGF expression and all dynamic MRI parameters. Kaplan-Meier curves based on k21 and SI-U/s showed that tumors with high k21 and SI-U/s values had a significantly (P < 0.05 and 0.001, respectively) worse disease outcome than did tumors with low k21 and SI-U/s values. None of the histomorphological gold standard markers for assessing tumor angiogenesis (MVD and VEGF) had any significant power to predict patient survival. It is concluded that in patients with uterine cervical cancer: (a) the pathophysiological basis for differences in dynamic MRI is MVD but not VEGF expression; (b) a functional, dynamic MRI approach (both standard and pharmacokinetic analysis) may be better suited to assess angiogenic activity in terms of patient survival than are the current histomorphological-based markers of tumor angiogenesis; and (c) compared with standard analysis, a simple pharmacokinetic analysis of time-intensity curves is not superior to assess MVD or patient survival.